Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats

Atherosclerosis

Volumn 198, Issue 2, 2008, Pages 320-331

  Castro, Michele M ^a   Rizzi, Elen ^a   Figueiredo Lopes, Lívia ^a   Fernandes, Karla ^a   Bendhack, Lusiane M ^b   Pitol, Dimitrius Leonardo ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Faculty of Pharmaceutical Sciences of Ribeirao Preto   (Brazil)

Author keywords

2K 1C hypertension; Doxycycline; Metalloproteinases; Renovascular hypertension; Vascular dysfunction

Indexed keywords

ANTIBODY; COLLAGEN; DOXYCYCLINE; ELASTIN; EOSIN; GELATIN; GELATINASE A; HEMATOXYLIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM; ENZYME IMMOBILIZATION; ENZYME INHIBITION; HEART MUSCLE RELAXATION; HYPERTENSION; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TISSUE SECTION; TREATMENT DURATION; VASCULAR DISEASE; VASCULAR RING; VASODILATATION; ZYMOGRAPHY;

ANIMALS; AORTA, THORACIC; DOXYCYCLINE; ENZYME PRECURSORS; GELATINASES; HYPERTENSION, RENAL; MALE; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; RATS; RATS, WISTAR; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASODILATION;

EID: 43949099942     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.011     Document Type: Article

References (47)

1. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
2. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69 (2006) 614-624
3. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
4. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
5. Yasmin, McEniery C.M., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 372
6. Bouvet C., Gilbert L.A., Girardot D., deBlois D., and Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 (2005) 432-437
7. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 (1999) 906-911
8. Fernandez-Patron C., Stewart K.G., Zhang Y., et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 (2000) 670-676
9. Martinez A., Oh H.R., Unsworth E.J., et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 (2004) 413-418
10. Lerman L.O., Chade A.R., Sica V., and Napoli C. Animal models of hypertension: an overview. J Lab Clin Med 146 (2005) 160-173
11. Lehoux S., Lemarie C.A., Esposito B., Lijnen H.R., and Tedgui A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodelling. Circulation 109 (2004) 1041-1047
12. Dao H.H., Lemay J., de Champlain J., deBlois D., and Moreau P. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 19 (2001) 1965-1973
13. Watts S.W., Rondelli C., Thakali K., et al. Morphologic and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol 292 (2007) H2438-H2448
14. Golub L.M., Lee H.M., Ryan M.E., et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12 (1998) 12-26
15. Pyo R., Lee J.K., Shipley J.M., et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105 (2000) 1641-1649
16. Palei A.C.T., Zaneti R.A.G., Fortuna G.M., Gerlach R.F., and Tanus-Santos J.E. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 5 (2005) 611-617
17. Castro M.M., Rizzi E., Rascado R.R., et al. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 498 (2004) 189-194
18. Escolar J.D., Tejero C., Escolar M.A., Montalvo F., and Garisa R. Architecture, elastic fiber, and collagen in the distal air portion of the lung of the 18-month-old rat. Anat Rec 248 (1997) 63-69
19. Escolar J.D., Tejero C., Escolar M.A., Montalvo F., and Garisa R. Methodological contributions for the morphometric study of the lung: approximation to the ideal sample size and quantification of collagen fiber. Anat Rec 247 (1997) 501-511
20. Verheyen A., Minten J., Cornelissen F., Rombauts W., and De Geest H. Determination of areal densities of blood vessel wall components in histological sections by means of image analysis. J Microsc 146 (1987) 201-208
21. Souza-Costa D.C., Figueiredo-Lopes L., Alves-Filho J.C., et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 35 (2007) 239-245
22. Souza-Costa D.C., Zerbini T., Palei A.C., Gerlach R.F., and Tanus-Santos J.E. L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Chest 128 (2005) 3705-3710
23. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38 (2005) 410-414
24. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344 (2005) 147-149
25. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40 (2007) 119-123
26. Arribas S.M., Hinek A., and Gonzalez M.C. Elastic fibres and vascular structure in hypertension. Pharmacol Ther 111 (2006) 771-791
27. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93 (2001) 178-193
28. Garcia-Touchard A., Henry T.D., Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 25 (2005) 1119-1127
29. Fortuna G.M., Figueiredo-Lopes L., Dias-Junior C.A.C., Gerlach R.F., and Tanus-Santos J.E. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 114 (2007) 22-27
30. Martinez M.L., Lopes L.F., Coelho E.B., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47 (2006) 117-122
31. Watts S.W., Rondelli C., Thakali K., et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol 292 (2007) H2438-H2448
32. Flamant M., Placier S., Dubroca C., et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50 (2007) 212-218
33. Bendeck M.P., Conte M., Zhang M., et al. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 160 (2002) 1089-1095
34. Courtman D.W., Franco C.D., Meng Q., and Bendeck M.P. Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J Vasc Res 41 (2004) 157-165
35. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
36. Li Z., Li L., Zielke H.R., et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148 (1996) 121-128
37. Galis Z.S., Sukhova G.K., Lark M.W., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
38. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., and Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 92 (1995) 402-406
39. Zaltsman A.B., and Newby A.C. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis 130 (1997) 61-70
40. Grote K., Flach I., Luchtefeld M., et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 92 (2003) e80-e86
41. Asanuma K., Magid R., Johnson C., et al. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol 284 (2003) H1778-H1784
42. Chesler N.C., Ku D.N., and Galis Z.S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 277 (1999) H2002-H2009
43. Moreau P., and Schiffrin E.L. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Can J Physiol Pharmacol 81 (2003) 511-521
44. Camp T.M., Tyagi S.C., Aru G.M., et al. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 23 (2004) 729-736
45. Jonat C., Chung F.Z., and Baragi V.M. Transcriptional downregulation of stromelysin by tetracycline. J Cell Biochem 60 (1996) 341-347
46. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
47. English J.L., Kassiri Z., Koskivirta I., et al. Individual timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 281 (2006) 10337-10346